News
Bharat Biotech’s Covid-19 vaccine to use ViroVax’s adjuvant for longer-lasting immunity
Vaccines major Bharat Biotech on Monday announced its coronavirus disease (Covid-19) vaccine Covaxin will use adjuvant Alhydroxiquim-II to boost immune response.
An adjuvant is a pharmacological or immunological agent that improves the immune response of a vaccine by producing more...
News
Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business
Omnicell, Inc., a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously announced acquisition of Pharmaceutical Strategies Group’s (PSG) 340B Link business, pursuant to the terms...
News
Siegfried to Acquire Two Pharmaceutical Manufacturing Sites from Novartis in Spain
Siegfried has signed binding agreements with Novartis regarding the acquisition of two pharmaceutical manufacturing sites in Spain. With this acquisition, Siegfried will significantly enhance its global production network in terms of capacity and technological capabilities and will achieve the...
News
BMS Announces Update on CheckMate -915 Evaluating Opdivo Plus Yervoy Versus Opdivo in Resected High-Risk Melanoma Patients
Bristol Myers Squibb announced results for the co-primary endpoint for CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo for patients who have had a complete surgical removal of stage IIIb/c/d or stage...
News
EMA starts first rolling review of a COVID-19 vaccine in the EU
EMA’s human medicines committee (CHMP) has started the first ‘rolling review’ of a COVID-19 vaccine, which is being developed by the company AstraZeneca in collaboration with the University of Oxford.
The start of the rolling review means that the committee...
News
AstraZeneca: COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India
The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
A standard review process triggered a voluntary pause to vaccination across all global trials on...
News
BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs
BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced that it has established a new affiliate in the United States of America, BIAL Biotech Investments Inc. (BIAL Biotech). This...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
